Literature DB >> 19281912

Assessing anaphylactic risk? Consider mast cell clonality.

Dean D Metcalfe, Lawrence B Schwartz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19281912      PMCID： PMC2782434          DOI： 10.1016/j.jaci.2009.02.003

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  19 in total

1.  Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells.

Authors:  Lawrence B Schwartz; Hae-Ki Min; Shunlin Ren; Han-Zhang Xia; Jiang Hu; Wei Zhao; George Moxley; Yoshihiro Fukuoka
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

2.  Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.

Authors:  Melody C Carter; Jamie A Robyn; Peter B Bressler; John C Walker; Gail G Shapiro; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2007-05-03       Impact factor: 10.793

Review 3.  Diagnostic value of tryptase in anaphylaxis and mastocytosis.

Authors:  Lawrence B Schwartz
Journal:  Immunol Allergy Clin North Am       Date:  2006-08       Impact factor: 3.479

4.  Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis.

Authors:  L B Schwartz; T R Bradford; C Rouse; A M Irani; G Rasp; J K Van der Zwan; P W Van der Linden
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

5.  The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis.

Authors:  L B Schwartz; K Sakai; T R Bradford; S Ren; B Zweiman; A S Worobec; D D Metcalfe
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

6.  IL-4 exacerbates anaphylaxis.

Authors:  Richard T Strait; Suzanne C Morris; Kristi Smiley; Joseph F Urban; Fred D Finkelman
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

7.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

Authors:  H Nagata; A S Worobec; C K Oh; B A Chowdhury; S Tannenbaum; Y Suzuki; D D Metcalfe
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

8.  Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation.

Authors:  Bettina M Jensen; Michael A Beaven; Shoko Iwaki; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Pharmacol Exp Ther       Date:  2007-10-09       Impact factor: 4.030

Review 9.  Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.

Authors:  P Valent; C Akin; L Escribano; M Födinger; K Hartmann; K Brockow; M Castells; W R Sperr; H C Kluin-Nelemans; N A T Hamdy; O Lortholary; J Robyn; J van Doormaal; K Sotlar; A W Hauswirth; M Arock; O Hermine; A Hellmann; M Triggiani; M Niedoszytko; L B Schwartz; A Orfao; H-P Horny; D D Metcalfe
Journal:  Eur J Clin Invest       Date:  2007-06       Impact factor: 4.686

10.  Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.

Authors:  K Brockow; C Jofer; H Behrendt; J Ring
Journal:  Allergy       Date:  2008-02       Impact factor: 13.146
View more
  13 in total

1.  Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  2011-10-27       Impact factor: 2.749

2.  Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis.

Authors:  Roberta Zanotti; Patrizia Bonadonna; Massimiliano Bonifacio; Anna Artuso; Donatella Schena; Maurizio Rossini; Omar Perbellini; Sabrina Colarossi; Marco Chilosi; Giovanni Pizzolo
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

3.  Kounis syndrome: a monster for the atopic patient.

Authors:  Nicholas G Kounis
Journal:  Cardiovasc Diagn Ther       Date:  2013-03

Review 4.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

Review 5.  Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

Authors:  A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 6.  Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?

Authors:  A Matito; M Carter
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

7.  World allergy organization guidelines for the assessment and management of anaphylaxis.

Authors:  F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Yehia M El-Gamal; Dennis K Ledford; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong
Journal:  World Allergy Organ J       Date:  2011-02-23       Impact factor: 4.084

8.  Concomitant chronic pulmonary diseases and their association with hospital outcomes in patients with anaphylaxis and other allergic conditions: a cohort study.

Authors:  Zuber D Mulla; F Estelle R Simons
Journal:  BMJ Open       Date:  2013-07-31       Impact factor: 2.692

Review 9.  Management and Prevention of Anaphylaxis.

Authors:  Anne-Marie Irani; Elias G Akl
Journal:  F1000Res       Date:  2015-12-22

Review 10.  Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders.

Authors:  P Valent
Journal:  Clin Exp Allergy       Date:  2014-07       Impact factor: 5.018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.